Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Waiting to discuss P1 on Oct 13 will not be a good sign

<< Previous

Bullboard Posts

Next >>

Post by Joemareon Sep 30, 2022 10:35am

256 Views

Post# 34997410

Waiting to discuss P1 on Oct 13 will not be a good sign

TH definately needs to come out with a PR before that date and use the 13th to further monetize on the momentum.
Waiting for Oct 13 for a business update will equate to excuses for not delivering resutls, not enough patients, etc. etc. Waiting for the 13th for news means they have nothing tangible to discuss. Just excuses.
Excuses = further punishement for shareholders. Further failure.

<< Previous

Bullboard Posts

Next >>

5 steps to mastering risk management in the stock market